未登录

K

Kumiko Koyama

translational research laboratories

H指数:24

被引数:4,043

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expression of HER2, HER3, and TROP2 in primary tumors and brain metastases of breast cancer

乳腺癌原发灶和脑转移灶中HER2、HER3和TROP2的表达

IF2.9

2026-03-130

PRE

The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy

HER3-DXd单药及与驱动癌基因抑制剂联用对HER3-DXd疗效的影响

International Journal of Molecular Sciences

IF4.9

2026-02-260

OAAI

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma

IF3

2023-08-013

OAAI

Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis

CANCER RESEARCH

IF16.6

2023-04-140

PRE

The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody- drug conjugate

CANCER RESEARCH

IF16.6

2023-04-042

PRE

HER3 expression after systemic therapy and clinical characteristics in patients with hepatocellular carcinoma

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Changes in HER3 expression associated with chemotherapy for pancreatic cancer

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Changes in HER3 expression profiles between primary and recurrent gynecological cancers

CANCER CELL INTERNATIONAL

IF6

2023-02-036

OAAI

Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2022-12-136

OAAI

Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)

CANCER RESEARCH

IF16.6

2022-02-152

PRE

U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression

CANCER RESEARCH

IF16.6

2020-08-153

PRE

Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Autophagy modulates intracellular dynamics of [fam-]trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)

CANCER RESEARCH

IF16.6

2019-07-010

PRE

U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits its antitumor activity through increased payload intracellular delivery via highly efficient drug internalization

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Pharmacological properties of a novel PI3Kd inhibitor, DS-1515

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-190

PRE

Disposition and biotransformation of [14C]-radiolabeled CS-7017 in healthy male subjects

CANCER RESEARCH

IF16.6

2011-04-010

PRE

CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2009-11-0170

OAAI

Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis

GENES CHROMOSOMES & CANCER

IF2.8

2000-07-2177

PREAI

Isolation and characterization of a novel TP53-inducible gene, TP53TG5, which suppresses growth and shows cell cycle-dependent transition of expression

GENES CHROMOSOMES & CANCER

IF2.8

2000-04-016

PREAI

EB3, a novel member of the EB1 family preferentially expressed in the central nervous system, binds to a CNS-specific APC homologue

EB3是EB1家族的新成员，优先在中枢神经系统中表达，与CNS特异性APC同源物结合。

IF7.3

2000-01-20111

PREAI